Skyworks Solutions (NasdaqGS:SWKS) Q1 2026 Earnings call February 03, 2026 04:30 PM ET Company ParticipantsPhilip Brace - CEO and PresidentPhilip Carter - CFO and SVPRaji Gill - Head of Investor RelationsConference Call ParticipantsChristopher Rolland - AnalystEdward Snyder - AnalystGary Mobley - AnalystHarsh Kumar - AnalystJim Schneider - AnalystKarl Ackerman - AnalystLiam Pharr - AnalystPeter Peng - AnalystTimothy Arcuri - AnalystOperatorGood afternoon, and welcome to Skyworks Solutions' first quarter fis ...

Financial Data and Key Metrics Changes - The company reported net bookings of $1.76 billion for Q3 2026, exceeding the high end of guidance by a significant margin [7][17] - GAAP net revenue increased by 25% to $1.7 billion, while cost of revenue rose by 26% to $754 million [18] - Operating expenses increased by 10% to $984 million, with management basis operating expenses rising 13% year-over-year [18][21] - The company raised its full fiscal year net bookings outlook to $6.65-$6.7 billion, representing an 18% growth compared to fiscal 2025 [7][19] Business Line Data and Key Metrics Changes - The mobile business saw a year-over-year growth of 19%, with Toon Blast growing 43% and Match Factory increasing by 17% [8][18] - NBA 2K series grew by 30%, while Grand Theft Auto Online increased by 27% [18][10] - Recurrent consumer spending rose by 23%, accounting for 76% of net bookings [17][18] Market Data and Key Metrics Changes - The mobile direct-to-consumer business achieved its strongest quarter on record, driven by enhancements in personalized offers and flexible pricing [9] - Advertising revenues grew by 10% year-over-year, supported by higher average revenue per daily active user [9] Company Strategy and Development Direction - The company is focusing on leveraging new technologies, particularly AI, to drive efficiencies and enhance creative processes [12] - The upcoming release of Grand Theft Auto VI is expected to significantly impact future net bookings and profitability [12][19] - The company aims to maintain a balance between organic growth and selective acquisitions, emphasizing the importance of creativity and innovation [42] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ongoing momentum of the business and the potential for record levels of net bookings in fiscal 2027 [12][23] - The regulatory environment is becoming more favorable for direct-to-consumer strategies, which are expected to enhance margins and profitability [9][35] Other Important Information - The company plans to provide its initial three-year pipeline for fiscal 2027 through fiscal 2029 in the Q4 results in May [16][23] - The release slate for the upcoming quarter includes several key titles, such as Sid Meier's Civilization VII and WWE 2K26 [22] Q&A Session Summary Question: Concerns about AI's impact on the business - Management clarified that the video game industry has always utilized machine learning and AI, and they are optimistic about the opportunities AI presents for efficiency and creativity [26][27] Question: Mobile business growth initiatives - Management highlighted the importance of creating hits and supporting talent, which has led to significant growth in mobile titles [32][33] Question: Capital allocation priorities - Management stated that capital will be used for organic growth, selective acquisitions, and returning capital to shareholders through buybacks [41][42] Question: Engagement with GTA Online - Management noted that both GTA V and GTA Online are seeing substantial engagement, with new content updates driving continued interest [39][86] Question: Future of GTA Online post-GTA VI release - Management indicated that support for GTA Online will continue, as the community remains engaged and new content is consistently delivered [58] Question: Mobile advertising growth - Management attributed growth in mobile advertising to the strategic addition of ad units and effective monetization without disrupting user experience [56] Question: Insights on user-generated content and developer economics - Management expressed interest in user-generated content and its potential to enhance engagement while maintaining a focus on high-quality entertainment [81][82]

Aytu Biopharma (NasdaqCM:AYTU) Q2 2026 Earnings call February 03, 2026 04:30 PM ET Company ParticipantsJosh Disbrow - Co-Founder, CEO, and DirectorRobert Blum - Managing PartnerRyan Selhorn - CFOConference Call ParticipantsEd Woo - Senior Research AnalystNaz Rahman - Senior Biotechnology Research AnalystThomas Flaten - Senior Research AnalystOperatorGood day, everyone, and welcome to the Aytu BioPharma Fiscal 2026 second quarter earnings call. At this time, all participants are placed on a listen-only mode, ...

Sonos (NasdaqGS:SONO) Q1 2026 Earnings call February 03, 2026 04:30 PM ET Company ParticipantsErik Woodring - Managing Director of Equity ResearchJames Baglanis - Head of Investor RelationsSaori Casey - CFOTom Conrad - CEOConference Call ParticipantsSteve Frankel - Director of Research and Senior Research AnalystNone - AnalystOperatorLadies and gentlemen, thank you for standing by. My name is Abby, and I will be your conference operator today. At this time, I would like to welcome everyone to the Sonos firs ...

H&R Block (NYSE:HRB) Q2 2026 Earnings call February 03, 2026 04:30 PM ET Speaker2day and thank you for standing by. Welcome to the H&R Block second quarter fiscal 2026 earnings conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during the session, you will need to press star 11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your questi ...

Financial Data and Key Metrics Changes - Amgen delivered a 10% sales growth in 2025, with 14 products achieving over $1 billion in annual sales and 18 products reaching record sales [21][32] - Non-GAAP operating margin for the full year was 46%, with R&D spending increasing by 22% year-over-year to a record $7.2 billion [32][33] - Free cash flow generated for the full year was $8.1 billion, reflecting operational momentum and effective working capital management [33] Business Line Data and Key Metrics Changes - Repatha sales grew 36% year-over-year, surpassing $3 billion, driven by increased urgency in treating patients [21][22] - Evenity sales increased by 34% to $2.1 billion, with a 41% growth in the U.S. market [21][23] - Uplizna sales rose 73% year-over-year to $655 million, reflecting strong demand across all approved indications [24][25] - The rare disease portfolio grew 14% year-over-year to nearly $5.2 billion [24] - Tezspire sales grew 52% year-over-year to nearly $1.5 billion, positioning it as a leading therapy for severe uncontrolled asthma [28] Market Data and Key Metrics Changes - The U.S. market for Repatha is seeing improved patient access through broad formulary coverage and the launch of Amgen Now, a direct-to-patient program [22] - Evenity leads the bone builder segment with over 60% market share, with a significant opportunity remaining as nearly 90% of high-risk women remain untreated [23] - Uplizna is the most prescribed FDA-approved therapy for NMOSD in the U.S., supported by consistent new patient growth [25] Company Strategy and Development Direction - Amgen is focusing on six key growth drivers for 2026: Repatha, Evenity, Tezspire, rare disease, innovative oncology, and biosimilars [34][35] - The company is committed to advancing innovation in areas of high unmet medical need while maintaining rigorous financial discipline [38] - Amgen is leveraging AI across the value chain to enhance therapeutic discovery and development [33] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth potential of MariTide and its differentiated treatment for obesity and related conditions [6][10] - The company anticipates 2026 total revenues in the range of $37.0 billion to $38.4 billion, with non-GAAP earnings per share between $21.60 and $23 [34][36] - Management acknowledged potential challenges from increased competition and pricing pressures but remains optimistic about the overall growth trajectory [36][38] Other Important Information - Amgen's innovative oncology portfolio grew 11% year-over-year, generating $8.7 billion in full-year sales [30] - The company is advancing multiple late-stage programs and has completed five key regulatory approvals in 2025 [9][19] Q&A Session All Questions and Answers Question: Insights on MariTide and obesity portfolio - Management highlighted the development of MariTide across various indications and expressed confidence in competing broadly in the obesity field [42][44] Question: Dazodalibep for primary Sjögren's syndrome - Management confirmed that both phase 3 studies are fully enrolled and expect completion later this year, expressing confidence in the drug's potential [47][49] Question: Uplizna's market opportunity and usage - Management discussed the potential for increased awareness and diagnosis of IgG4-related disease, noting strong initial uptake of Uplizna [51][56] Question: Confidence in Uplizna's phase 3 study in CIDP - Management expressed optimism about Uplizna's unique mechanism of action and the potential to help patients with CIDP [60][63] Question: Repatha's prescription sources and market evolution - Management indicated that approximately 40% of Repatha prescriptions come from primary care, with expectations for growth following the VASILIS data promotion [72][74] Question: Tepezza and AMG 732 for TED - Management confirmed ongoing studies for Tepezza and expressed confidence in its strong evidence base and market position [77][80]

Sonos (NasdaqGS:SONO) Q1 2026 Earnings call February 03, 2026 04:30 PM ET Speaker2Ladies and gentlemen, thank you for standing by. My name is Abby, and I will be your conference operator today. At this time, I would like to welcome everyone to the Sonos first quarter fiscal 2026 conference call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during that time, simply press star f ...

Emerson Electric (NYSE:EMR) Q1 2026 Earnings call February 03, 2026 04:30 PM ET Speaker2Greetings and welcome to the Emerson First Quarter 2026 Earnings Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. If anyone should require operator assistance, please press star zero on your telephone keypad. As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Doug Ashby, Director of In ...

National Research (NasdaqGS:NRC) Q4 2025 Earnings call February 03, 2026 04:30 PM ET Speaker1Good afternoon. Thank you for attending today's NRC fourth quarter 2025 results. My name is Victoria, and I'll be your moderator today. I would now like to pass the conference over to Jordan Freeman. Thank you. You may proceed, Jordan.Speaker0Welcome to NRC Health Earnings Conference Call for the fourth quarter ended December 31, 2025. I wanted to first let you know that we've posted our earnings press release to th ...

Chipotle (NYSE:CMG) Q4 2025 Earnings call February 03, 2026 04:30 PM ET Speaker2Good day and welcome to the Chipotle Mexican Grill fourth quarter and full year 2025 results conference call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by 0. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star then 1 on a touch-tone phone. To withdraw your question, ...